Arcturus Therapeutics Holdings Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Arcturus terminated its sa-mRNA collaboration with CSL Seqirus and regained global rights to KOSTAIVE and infectious disease vaccine portfolio (seasonal flu, pandemic flu, RSV, EBV). CSL Seqirus paid $12 million cash and released $16 million in R&D liabilities/credits. ARCT-032 (CF) Phase 2 enrollment on track; Phase 3 decision expected Q4 2026 with Thermo Fisher support. ARCT-810 (OTC) Phase 2 dosing complete; data due Q3 2026. Cash position: $191.5M (down from $230.9M YE2025); cash runway extends through 2028.
Why this rating
Portfolio reacquisition + $28M net benefit (~8.7% of market cap) moderately strengthens balance sheet; strategic vaccine control recovered. Pipeline progress encouraging but early-stage. Moderate for $323.5M biotech given clinical stage, cash burn, and dependent on Phase outcomes.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.